Aceto Corporation Announces Natasha Giordano Will Stand for Election to the Board of Directors


PORT WASHINGTON, N.Y., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals today announced that Natasha Giordano, age 51, has been nominated to stand for election to the Company's Board of Directors. 

Albert Eilender, Chairman and CEO of Aceto commented, "We are extremely pleased to have Ms. Giordano stand for Board election at our December 8, 2011 Annual meeting as an independent director. With 20+ years of experience in positions of senior leadership in the healthcare and pharmaceutical industries, she clearly brings to our Board a vast amount of practical experience in general management, strategy, marketing, sales development, and compliance.   We are excited to have someone with Natasha's background and qualifications serve on our Board as an independent director, and are confident that our shareholders will be equally enthused."

Ms. Giordano currently serves as President, CEO and Director of Xanodyne Pharmaceuticals, Inc. a branded specialty pharmaceutical company with development and commercial capabilities focused on pain management. Prior to that she spent eight years, most recently as President- Americas with Cegedim Dendrite and nine years with Parke-Davis then owned by Warner Lambert in several sales and marketing positions including Strategic Alliance management and Sales Integration.

Prior to her executive assignments, Ms. Giordano had managed sales teams bringing new products to market through both direct sales to institutions and physicians as well as to the distribution sources that supply most pharmacies and health provider organizations. Her breadth of experience spans specialty and larger pharmaceuticals companies as well as technology service providers to the industry. Ms. Giordano holds a Bachelor of Science degree from Wagner College and is a Registered Nurse.

Mr. Eilender further commented, "The Board addition of Ms. Giordano, the recent appointment of Sal Guccione as President and COO, commencing on or about December 1, 2011, the recent management addition of Nicholas Shackley as SVP Active Pharmaceutical Ingredients and the assignment of Frank DeBenedittis to SVP Business Development, evidences management's and the Board of Directors' commitment to succession planning and its strategic focus on generating sustainable future growth as a supplier of health related products, i.e. pharmaceutical ingredients, intermediates and branded generic drugs."

ABOUT ACETO

Aceto Corporation, incorporated in 1947, is a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. With business operations in ten countries, Aceto distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. Aceto's global operations, including a staff of 26 in China and 12 in India are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. (ACET-F)

This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this news release may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of Aceto's plans or strategies, financing plans, projected or anticipated benefits from acquisitions that Aceto may make, or projections involving anticipated revenues, earnings or other aspects of Aceto's operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. Aceto intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company's strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth.  Aceto cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond Aceto's control, which may influence the accuracy of the statements and the projections upon which the statements are based.  Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in Aceto's reports filed with the Securities and Exchange Commission, including, but not limited to, Aceto's Annual Report or Form 10-K for the fiscal year ended June 30, 2011 and other filings. Copies of these filings are available at http://www.sec.gov/blocked::http://www.sec.gov/">www.sec.gov.   

Any one or more of these uncertainties, risks and other influences could materially affect Aceto's results of operations and whether forward-looking statements made by Aceto ultimately prove to be accurate.  Aceto's actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements.  Aceto undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.



            

Contact Data